A real-world pharmacovigilance study of FDA Adverse Event Reporting System events for gefitinib and docetaxel
Related Experiment Video
Updated: Sep 8, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Chengqian Cui1, Bingge Li2, Xiaoxia Zhang3
1Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Background:
In recent years, gefitinib and docetaxel, as targeted and chemotherapeutic agents, respectively, have been widely used in the treatment of non-small cell lung cancer (NSCLC). However, the safety of these drugs remains a significant concern in clinical practice. Comparative studies on the safety of these two drugs have yet to be fully explored. This study aimed to analyze adverse event (AE) signals associated with gefitinib and docetaxel in the treatment of NSCLC using the FDA Adverse Event Reporting System (FAERS), providing insights for clinical practice and package insert.
Methods:
Adverse events for gefitinib and docetaxel were retrieved from the FDA Adverse Event Reporting System (FAERS) from the first quarter of 2004 (2004 Q1) through the fourth quarter of 2024 (2024 Q4). The reporting odds ratio method was used to identify risk signals. The results were standardized and classified using the System Organ Class (SOC) and Preferred Terms (PT) in the 26.1 version of the Medical Dictionary for Regulatory Activities (MedDRA) and compared with the package insert.
Results:
The FAERS received 8214 and 42,453 AE reports for gefitinib and docetaxel, respectively. An analysis of the top 100 AEs ranked by signal strength revealed 64 positive PTs for gefitinib, spanning 14 SOCs, 45 of which were not mentioned in the package insert. For docetaxel, 61 positive PTs were identified, involving 15 SOCs, with 33 AEs not mentioned in the package insert. The top 5 PTs with the highest signal strength for gefitinib were PRIDE syndrome, drug resistance, lymphangiosis carcinomatosa, xeroderma, and skin disorder. For docetaxel, the top 5 PTs were lacrimal structure injury, madarosis, hair disorder, variations in hair color, and psychological trauma.
Conclusion:
The potential adverse reactions of gefitinib and docetaxel are not fully covered in their package insert. The newly identified AE signals provide critical evidence for the improvement of the package insert. These findings have significant implications for individualized clinical treatment.
Insights
This study analyzed adverse event signals for gefitinib and docetaxel in non-small cell lung cancer (NSCLC) patients using FDA data. Many potential drug safety issues were not listed in current drug information, highlighting needs for updated safety profiles.
Area of Science:
- Pharmacovigilance and Drug Safety
- Oncology and Cancer Therapeutics
- Regulatory Science
Background:
- Gefitinib (targeted therapy) and docetaxel (chemotherapy) are key treatments for non-small cell lung cancer (NSCLC).
- Clinical safety concerns persist for both gefitinib and docetaxel in NSCLC management.
- Comparative safety analyses of these agents require further exploration.
Purpose of the Study:
- To identify and analyze adverse event (AE) signals for gefitinib and docetaxel in NSCLC treatment.
- To compare identified AE signals with existing package insert information.
- To provide evidence for updating drug safety information and guiding clinical practice.
Main Methods:
- Retrieved AE data for gefitinib and docetaxel from the FDA Adverse Event Reporting System (FAERS) (2004-2024).
- Employed the reporting odds ratio method to detect significant AE risk signals.
- Classified AEs using Medical Dictionary for Regulatory Activities (MedDRA) terms and compared findings with drug labels.
Main Results:
- Identified 64 positive AE signals for gefitinib (14 System Organ Classes), with 45 not listed in its package insert.
- Identified 61 positive AE signals for docetaxel (15 System Organ Classes), with 33 not listed in its package insert.
- Top signals for gefitinib included PRIDE syndrome and drug resistance; for docetaxel, lacrimal structure injury and hair disorders were prominent.
Conclusions:
- Current package inserts for gefitinib and docetaxel may not fully encompass all potential adverse reactions.
- Newly identified AE signals underscore the need for updating drug safety information and package inserts.
- Findings support more individualized clinical treatment strategies based on comprehensive AE profiles.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
08:41Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
Related Concept Videos
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:25Drug Regulation
01:11Clinical Trials: Overview
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...